Nutraceutical formulation with cocoa polyphenols and physalis peruviana extract for gestational diabetes prevention

Overview

Gestational diabetes is a growing health concern affecting pregnant women, with potential negative consequences for both mother and fetus. This research proposes an innovative nutraceutical formulation that combines cocoa polyphenols and Physalis peruviana extract, both recognized for their antioxidant, anti-inflammatory, and blood sugar-regulating properties. The product is designed as a functional food delivery system using 3D printing technology and advanced encapsulation methods to ensure optimal bioavailability of the bioactive compounds.

The solution targets a critical unmet need: safe, nutrition-based strategies to prevent or manage gestational diabetes. By integrating well-characterized natural bioactives into a stable, palatable, and precisely dosed food format, this nutraceutical offers a preventive approach that aligns with dietary recommendations during pregnancy.

Technical specifications

Key features:

• Novel extraction and purification methods for cocoa polyphenols and Physalis peruviana withanolides
• Encapsulation technologies with high efficiency to protect bioactives and enhance bioavailability
• In vitro bioaccessibility confirmation of encapsulated extracts
• 3D-printed functional food matrix incorporating bioactive compounds, with optimized manufacturing parameters (temperature, nozzle size, layer deposition)
• Cell and animal models demonstrating effects on glucose metabolism and insulin resistance reversal

Research capabilities:

• Established cell and animal models for diabetes and gestational diabetes
• Chemical analysis methods to verify content and stability of polyphenols and Physalis peruviana extract in the final product
• Sensory evaluation protocols for consumer acceptability

Technology readiness level

The project is currently at an early-to-mid stage of development. Preliminary in vitro and animal data have been obtained demonstrating biological effects of cocoa polyphenols and Physalis peruviana extract on glucose metabolism and insulin resistance. Extraction, purification, and encapsulation methodologies have been established, and initial bioaccessibility studies have been completed.

Future validation steps include optimizing encapsulation conditions, finalizing the 3D printing process, conducting sensory evaluations, performing chemical stability analysis, and completing rigorous toxicity and safety assessments in cell, animal, and pregnancy-specific models. Ethical approval for human, animal, and cell studies will be obtained from Universidad Industrial de Santander before clinical translation. The technology is not yet ready for commercial deployment and requires further preclinical and clinical validation.